|
1
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ciriello G, Miller ML, Aksoy BA,
Senbabaoglu Y, Schultz N and Sander C: Emerging landscape of
oncogenic signatures across human cancers. Nat Genet. 45:1127–1133.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janku F, Hong DS, Fu S, Piha-Paul SA,
Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee
JJ, et al: Assessing PIK3CA and PTEN in early-phase trials with
PI3K/AKT/mTOR inhibitors. Cell Rep. 6:377–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janku F, Wheler JJ, Naing A, Stepanek VM,
Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA,
Moulder SL, et al: PIK3CA mutations in advanced cancers:
Characteristics and outcomes. Oncotarget. 3:1566–1575. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zaytseva YY, Valentino JD, Gulhati P and
Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aoki M, Blazek E and Vogt PK: A role of
the kinase mTOR in cellular transformation induced by the
oncoproteins P3k and Akt. Proc Natl Acad Sci USA. 98:pp. 136–141.
2001; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guba M, von Breitenbuch P, Steinbauer M,
Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S,
Anthuber M, et al: Rapamycin inhibits primary and metastatic tumor
growth by antiangiogenesis: Involvement of vascular endothelial
growth factor. Nat Med. 8:128–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dupont P and Warrens AN: The evolving role
of sirolimus in renal transplantation. QJM. 96:401–409. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leystra AA, Deming DA, Zahm CD, Farhoud M,
Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan
R, et al: Mice expressing activated PI3K rapidly develop advanced
colon cancer. Cancer Res. 72:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deming DA, Leystra AA, Farhoud M,
Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R,
Weichert JP and Halberg RB: mTOR inhibition elicits a dramatic
response in PI3K-dependent colon cancers. PLoS One. 8:e607092013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park HS, Lim SM, Kim S, Kim S, Kim HR,
Kwack K, Lee MG, Kim JH and Moon YW: Pilot study of a
next-generation sequencing-based targeted anticancer therapy in
refractory solid tumors at a Korean Institution. PLoS One.
11:e01541332016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Hoff DD, Stephenson JJ Jr, Rosen P,
Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N,
Richards DA, et al: Pilot study using molecular profiling of
patients' tumors to find potential targets and select treatments
for their refractory cancers. J Clin Oncol. 28:4877–4883. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsimberidou AM, Iskander NG, Hong DS,
Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra
R, et al: Personalized Medicine in a phase i clinical trials
program: The MD Anderson cancer center initiative. Clin Cancer Res.
18:6373–6383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
PIK3CA mutations predict response to
PI3K/AKT/mTOR inhibitors. Cancer Discovery. 2:205. 2012.
|
|
24
|
Kim ST, Lee J, Park SH, Park JO, Park YS,
Kang WK and Lim HY: Prospective phase II trial of everolimus in
PIK3CA amplification/mutation and/or PTEN loss patients with
advanced solid tumors refractory to standard therapy. BMC Cancer.
17:2112017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rizell M, Andersson M, Cahlin C, Hafström
L, Olausson M and Lindnér P: Effects of the mTOR inhibitor
sirolimus in patients with hepatocellular and cholangiocellular
cancer. Int J Clin Oncol. 13:66–70. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reardon DA, Quinn JA, Vredenburgh JJ,
Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon
JE II, Dowell JM, McLendon RE, et al: Phase 1 trial of gefitinib
plus sirolimus in adults with recurrent malignant glioma. Clin
Cancer Res. 12:860–868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martin-Liberal J, Gil-Martín M,
Sáinz-Jaspeado M, Gonzalo N, Rigo R, Colom H, Muñoz C, Tirado OM
and García del Muro X: Phase I study and preclinical efficacy
evaluation of the mTOR inhibitor sirolimus plus gemcitabine in
patients with advanced solid tumours. Br J Cancer. 111:858–865.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Desar IM, Timmer-Bonte JN, Burger DM, van
der Graaf WT and van Herpen CM: A phase I dose-escalation study to
evaluate safety and tolerability of sorafenib combined with
sirolimus in patients with advanced solid cancer. Br J Cancer.
103:1637–1643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dueck AC, Mendoza TR, Mitchell SA, Reeve
BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM,
O'Mara AM, et al: Validity and reliability of the US national
cancer institute's patient-reported outcomes version of the common
terminology criteria for adverse Events (PRO-CTCAE). JAMA Oncol.
1:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsuoka T and Yashiro M: The role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers. 6:1441–1463.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu L, Wu N and Li J: Novel targeted
agents for gastric cancer. J Hematol Oncol. 5:312012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung
HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, et al: Everolimus
for previously treated advanced gastric cancer: Results of the
randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol.
31:3935–3943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seront E, Pinto A, Bouzin C, Bertrand L,
Machiels JP and Feron O: PTEN deficiency is associated with reduced
sensitivity to mTOR inhibitor in human bladder cancer through the
unhampered feedback loop driving PI3K/Akt activation. Br J Cancer.
109:1586–1592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Weigelt B, Warne PH and Downward J: PIK3CA
mutation, but not PTEN loss of function, determines the sensitivity
of breast cancer cells to mTOR inhibitory drugs. Oncogene.
30:3222–3233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chaft JE, Arcila ME, Paik PK, Lau C, Riely
GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M and Kris
MG: Coexistence of PIK3CA and other oncogene mutations in lung
adenocarcinoma-rationale for comprehensive mutation profiling. Mol
Cancer Ther. 11:485–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol.
30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park JH, Ryu MH, Park YS, Park SR, Na YS,
Rhoo BY and Kang YK: Successful control of heavily pretreated
metastatic gastric cancer with the mTOR inhibitor everolimus
(RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
BMC Cancer. 15:1192015. View Article : Google Scholar : PubMed/NCBI
|
